OBJECTIVE: To determine whether hyperglycemia exerts deleterious effects via cerebral energy metabolism and to illuminate the effects of cerebral high/low glucose in patients with aneurysmal subarachnoid hemorrhage. DESIGN AND SETTING: Prospective, nonrandomized single-center study over a 2-year period in an intensive care unit at a primary-level university hospital. PATIENTS: 28 subarachnoid hemorrhage patients (age 53 +/- 10 years, WFNS grade 2.8 +/- 1.5) classified as asymptomatic (n = 5) or symptomatic with acute focal or delayed ischemic neurological deficits (n = 23). MEASUREMENTS AND RESULTS: Hyperglycemia (> 7.8 mmol/l; >140 mg/dl) was more frequent in symptomatic patients and was reflected in higher glycerol concentrations than in asymptomatic patients. In all patients a microdialysis catheter was inserted into the tissue at risk; dialysates were collected hourly for 10 days. Cerebral low-glucose episodes (0.6 mmol/l) and high-glucose episodes (>2.6 mmol/l) occurred independently of blood glucose levels. During high-glucose episodes cerebral microdialysate levels were normal, while cerebral low glucose, occurring more frequently in symptomatic patients, was associated with severe cellular distress (increase in lactate/pyruvate ratio, glutamate, glycerol) and with unfavorable outcome if combined with hyperglycemia. CONCLUSIONS: Although hyperglycemia was more frequent in symptomatic patients and associated with high glycerol levels, hyperglycemia was not related to cerebral high glucose. It appears that the association of adverse outcome with acute-phase hyperglycemia is not mediated by cerebral glucose metabolism. Cerebral low glucose was associated with severe metabolic distress and may present a target for therapy to improve clinical outcome.
OBJECTIVE: To determine whether hyperglycemia exerts deleterious effects via cerebral energy metabolism and to illuminate the effects of cerebral high/low glucose in patients with aneurysmal subarachnoid hemorrhage. DESIGN AND SETTING: Prospective, nonrandomized single-center study over a 2-year period in an intensive care unit at a primary-level university hospital. PATIENTS: 28 subarachnoid hemorrhagepatients (age 53 +/- 10 years, WFNS grade 2.8 +/- 1.5) classified as asymptomatic (n = 5) or symptomatic with acute focal or delayed ischemic neurological deficits (n = 23). MEASUREMENTS AND RESULTS:Hyperglycemia (> 7.8 mmol/l; >140 mg/dl) was more frequent in symptomatic patients and was reflected in higher glycerol concentrations than in asymptomatic patients. In all patients a microdialysis catheter was inserted into the tissue at risk; dialysates were collected hourly for 10 days. Cerebral low-glucose episodes (0.6 mmol/l) and high-glucose episodes (>2.6 mmol/l) occurred independently of blood glucose levels. During high-glucose episodes cerebral microdialysate levels were normal, while cerebral low glucose, occurring more frequently in symptomatic patients, was associated with severe cellular distress (increase in lactate/pyruvate ratio, glutamate, glycerol) and with unfavorable outcome if combined with hyperglycemia. CONCLUSIONS: Although hyperglycemia was more frequent in symptomatic patients and associated with high glycerol levels, hyperglycemia was not related to cerebral high glucose. It appears that the association of adverse outcome with acute-phase hyperglycemia is not mediated by cerebral glucose metabolism. Cerebral low glucose was associated with severe metabolic distress and may present a target for therapy to improve clinical outcome.
Authors: Paul Vespa; Marvin Bergsneider; Nayoa Hattori; Hsiao-Ming Wu; Sung-Cheng Huang; Neil A Martin; Thomas C Glenn; David L McArthur; David A Hovda Journal: J Cereb Blood Flow Metab Date: 2005-06 Impact factor: 6.200
Authors: Neeraj Badjatia; Mehmet A Topcuoglu; Ferdinando S Buonanno; Eric E Smith; Raul G Nogueira; Guy A Rordorf; Bob S Carter; Christopher S Ogilvy; Aneesh B Singhal Journal: Crit Care Med Date: 2005-07 Impact factor: 7.598
Authors: Jens P Dreier; Johannes Woitzik; Martin Fabricius; Robin Bhatia; Sebastian Major; Chistoph Drenckhahn; Thomas-Nicolas Lehmann; Asita Sarrafzadeh; Lisette Willumsen; Jed A Hartings; Oliver W Sakowitz; Jörg H Seemann; Anja Thieme; Martin Lauritzen; Anthony J Strong Journal: Brain Date: 2006-10-25 Impact factor: 13.501
Authors: Paul Vespa; Robert Boonyaputthikul; David L McArthur; Chad Miller; Maria Etchepare; Marvin Bergsneider; Thomas Glenn; Neil Martin; David Hovda Journal: Crit Care Med Date: 2006-03 Impact factor: 7.598
Authors: Mark Parkin; Sarah Hopwood; Deborah A Jones; Parastoo Hashemi; Hans Landolt; Martin Fabricius; Martin Lauritzen; Martyn G Boutelle; Anthony J Strong Journal: J Cereb Blood Flow Metab Date: 2005-03 Impact factor: 6.200
Authors: Roman Hlatky; Alex B Valadka; J Clay Goodman; Charles F Contant; Claudia S Robertson Journal: J Neurotrauma Date: 2004-07 Impact factor: 5.269
Authors: Asita Sarrafzadeh; Daniel Haux; Ingeborg Küchler; Wolfgang R Lanksch; Andreas W Unterberg Journal: J Neurosurg Date: 2004-03 Impact factor: 5.115
Authors: Delphine Feuerstein; Andrew Manning; Parastoo Hashemi; Robin Bhatia; Martin Fabricius; Christos Tolias; Clemens Pahl; Max Ervine; Anthony J Strong; Martyn G Boutelle Journal: J Cereb Blood Flow Metab Date: 2010-02-10 Impact factor: 6.200
Authors: Andrew M Naidech; Kimberly Levasseur; Storm Liebling; Rajeev K Garg; Michael Shapiro; Michael L Ault; Sherif Afifi; H Hunt Batjer Journal: Neurocrit Care Date: 2010-04 Impact factor: 3.210
Authors: Freya M van Iersel; Arjen J C Slooter; Renee Vroegop; Annemiek E Wolters; Charlotte A M Tiemessen; Rik H J Rösken; Johannes G van der Hoeven; Linda M Peelen; Cornelia W E Hoedemaekers Journal: Intensive Care Med Date: 2012-08-21 Impact factor: 17.440
Authors: Jens P Dreier; Sebastian Major; Andrew Manning; Johannes Woitzik; Chistoph Drenckhahn; Jens Steinbrink; Christos Tolias; Ana I Oliveira-Ferreira; Martin Fabricius; Jed A Hartings; Peter Vajkoczy; Martin Lauritzen; Ulrich Dirnagl; Georg Bohner; Anthony J Strong Journal: Brain Date: 2009-05-06 Impact factor: 13.501